| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
356.90(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
31,500 |
| Total Buy Value |
$0 |
$0 |
$863 |
$138,033 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roberts M Scot |
Chief Scientific Officer |
• – – |
2024-02-02 |
4 |
D |
$9.32 |
$21,716 |
D/D |
(2,330) |
42,660 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2024-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,775 |
44,990 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2024-02-02 |
4 |
D |
$9.32 |
$78,064 |
D/D |
(8,376) |
292,028 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2024-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,950 |
300,404 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2024-02-02 |
4 |
D |
$9.32 |
$21,734 |
D/D |
(2,332) |
53,633 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2024-02-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,775 |
55,965 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2024-02-01 |
4 |
D |
$9.88 |
$17,794 |
D/D |
(1,801) |
37,215 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,166 |
39,016 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2024-02-01 |
4 |
D |
$9.88 |
$72,252 |
D/D |
(7,313) |
281,454 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,545 |
288,767 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2024-02-01 |
4 |
D |
$9.88 |
$17,794 |
D/D |
(1,801) |
48,190 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2024-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,166 |
49,991 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2024-01-31 |
4 |
A |
$2.69 |
$15,763 |
D/D |
5,860 |
32,850 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2024-01-31 |
4 |
A |
$2.69 |
$21,221 |
D/D |
7,889 |
272,222 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2024-01-31 |
4 |
A |
$2.69 |
$12,430 |
D/D |
4,621 |
45,012 |
|
- |
|
| Jordt Raymond M |
Chief Business Officer |
• – – |
2024-01-31 |
4 |
A |
$2.69 |
$13,531 |
D/D |
5,030 |
13,743 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2024-01-31 |
4 |
A |
$2.69 |
$8,761 |
D/D |
3,257 |
43,825 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2024-01-30 |
4 |
D |
$9.80 |
$26,548 |
D/D |
(2,709) |
26,990 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2024-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,275 |
29,699 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2024-01-30 |
4 |
D |
$9.80 |
$114,631 |
D/D |
(11,697) |
264,333 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2024-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,775 |
276,030 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2024-01-30 |
4 |
D |
$9.80 |
$21,315 |
D/D |
(2,175) |
40,391 |
|
- |
|
| Eisenstadt Richard I |
Chief Financial Officer |
• – – |
2024-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,275 |
42,566 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2024-01-30 |
4 |
D |
$9.80 |
$26,548 |
D/D |
(2,709) |
40,568 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2024-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,275 |
43,277 |
|
- |
|
417 Records found
|
|
Page 1 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.06 (0.83%) 
